NM_000350.3(ABCA4):c.5882G>A (p.Gly1961Glu) AND Severe early-childhood-onset retinal dystrophy
- Germline classification:
- Pathogenic/Likely pathogenic (18 submissions)
- Last evaluated:
- May 29, 2024
- Review status:
- 2 stars out of maximum of 4 starscriteria provided, multiple submitters, no conflicts
- Somatic classification
of clinical impact: - None
- Review status:
- (0/4) 0 stars out of maximum of 4 starsno assertion criteria provided
- Somatic classification
of oncogenicity: - None
- Review status:
- (0/4) 0 stars out of maximum of 4 starsno assertion criteria provided
- Record status:
- current
- Accession:
- RCV000008340.41
Allele description [Variation Report for NM_000350.3(ABCA4):c.5882G>A (p.Gly1961Glu)]
NM_000350.3(ABCA4):c.5882G>A (p.Gly1961Glu)
- Gene:
- ABCA4:ATP binding cassette subfamily A member 4 [Gene - OMIM - HGNC]
- Variant type:
- single nucleotide variant
- Cytogenetic location:
- 1p22.1
- Genomic location:
- Preferred name:
- NM_000350.3(ABCA4):c.5882G>A (p.Gly1961Glu)
- HGVS:
- NC_000001.11:g.94008251C>T
- NG_009073.1:g.117899G>A
- NG_009073.2:g.117897G>A
- NM_000350.3:c.5882G>AMANE SELECT
- NM_001425324.1:c.5660G>A
- NP_000341.2:p.Gly1961Glu
- NP_000341.2:p.Gly1961Glu
- NP_001412253.1:p.Gly1887Glu
- NC_000001.10:g.94473807C>T
- NM_000350.2:c.5882G>A
- P78363:p.Gly1961Glu
This HGVS expression did not pass validation- Protein change:
- G1887E; GLY1961GLU
- Links:
- UniProtKB: P78363#VAR_008475; OMIM: 601691.0007; dbSNP: rs1800553
- NCBI 1000 Genomes Browser:
- rs1800553
- Molecular consequence:
- NM_000350.3:c.5882G>A - missense variant - [Sequence Ontology: SO:0001583]
- NM_001425324.1:c.5660G>A - missense variant - [Sequence Ontology: SO:0001583]
- Observations:
- 6
Condition(s)
- Name:
- Severe early-childhood-onset retinal dystrophy (STGD1)
- Synonyms:
- MACULAR DYSTROPHY WITH FLECKS, TYPE 1; STGD; Stargardt macular dystrophy; See all synonyms [MedGen]
- Identifiers:
- MONDO: MONDO:0009549; MeSH: D000080362; MedGen: C1855465; Orphanet: 827; OMIM: 248200
Assertion and evidence details
Submission Accession | Submitter | Review Status (Assertion method) | Clinical Significance (Last evaluated) | Origin | Method | Citations |
---|---|---|---|---|---|---|
SCV000028548 | OMIM | no assertion criteria provided | Pathogenic (Jul 1, 2008) | germline | literature only | |
SCV000267674 | Lupski Lab, Baylor-Hopkins CMG, Baylor College of Medicine | criteria provided, single submitter (Lee et al. (Hum Genet 2016)) | Likely pathogenic | germline | research | |
SCV000281939 | Institute of Human Genetics, Univ. Regensburg, Univ. Regensburg | criteria provided, single submitter (Schulz et al. (Invest Ophthalmol Vis Sci. 2017)) | Pathogenic (Jan 1, 2016) | germline | clinical testing | |
SCV000494247 | Knight Diagnostic Laboratories, Oregon Health and Sciences University - CSER-NextGen | criteria provided, single submitter (ACMG Guidelines, 2015) | Pathogenic (Jun 28, 2016) | germline | clinical testing | |
SCV000607275 | GenomeConnect, ClinGen | no classification provided | not provided | unknown | phenotyping only | |
SCV000891470 | Department Of Genetics, Sultan Qaboos University Hospital, Sultan Qaboos University | criteria provided, single submitter (ACMG Guidelines, 2015) | Likely pathogenic (Dec 30, 2017) | unknown | curation | |
SCV001135328 | Mendelics | criteria provided, single submitter (Mendelics Assertion Criteria 2017) | Likely pathogenic (May 28, 2019) | unknown | clinical testing | |
SCV001521357 | Baylor Genetics | criteria provided, single submitter (ACMG Guidelines, 2015) | Pathogenic (Jan 17, 2020) | unknown | clinical testing | |
SCV001548126 | Institute of Medical Molecular Genetics, University of Zurich | criteria provided, single submitter (ACMG Guidelines, 2015) | Likely pathogenic (Jan 30, 2021) | germline | clinical testing | |
SCV001976708 | Laboratory of Medical Genetics, National & Kapodistrian University of Athens | criteria provided, single submitter (ACMG Guidelines, 2015) | Pathogenic (Oct 1, 2021) | maternal | clinical testing | |
SCV002058783 | 3billion | criteria provided, single submitter (ACMG Guidelines, 2015) | Likely pathogenic (Jan 3, 2022) | germline | clinical testing | PubMed (1) PMID:9295268, |
SCV002100408 | Genome-Nilou Lab | criteria provided, single submitter (ACMG Guidelines, 2015) | Pathogenic (Sep 10, 2021) | germline | clinical testing | |
SCV002526676 | Institute of Human Genetics, University of Leipzig Medical Center | criteria provided, single submitter (ACMG Guidelines, 2015) | Pathogenic (May 29, 2024) | unknown | clinical testing | |
SCV002564625 | Arcensus | criteria provided, single submitter (ACMG Guidelines, 2015) | Likely pathogenic (Feb 1, 2013) | germline | clinical testing | |
SCV002581171 | MGZ Medical Genetics Center | criteria provided, single submitter (ACMG Guidelines, 2015) | Pathogenic (Jul 26, 2022) | germline | clinical testing | |
SCV002767263 | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute
| criteria provided, single submitter (ACMG Guidelines, 2015) | Pathogenic (Sep 2, 2022) | germline | clinical testing | |
SCV004048390 | Neuberg Centre For Genomic Medicine, NCGM | criteria provided, single submitter (ACMG Guidelines, 2015) | Pathogenic | germline | clinical testing | |
SCV004806246 | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | criteria provided, single submitter (ACMG Guidelines, 2015) | Likely pathogenic (Mar 25, 2024) | germline | clinical testing |
Summary from all submissions
Ethnicity | Origin | Affected | Individuals | Families | Chromosomes tested | Number Tested | Family history | Method |
---|---|---|---|---|---|---|---|---|
not provided | germline | yes | 6 | not provided | not provided | 336 | yes | clinical testing, research |
not provided | germline | unknown | not provided | not provided | not provided | not provided | not provided | clinical testing |
not provided | unknown | unknown | not provided | not provided | not provided | not provided | not provided | clinical testing, phenotyping only |
not provided | germline | no | 1 | not provided | not provided | not provided | yes | clinical testing, research |
not provided | germline | not provided | not provided | not provided | not provided | not provided | not provided | literature only |
not provided | unknown | yes | not provided | not provided | not provided | not provided | not provided | clinical testing, curation |
not provided | maternal | yes | not provided | not provided | not provided | not provided | not provided | clinical testing |
Citations
PubMed
Allikmets R, Singh N, Sun H, Shroyer NF, Hutchinson A, Chidambaram A, Gerrard B, Baird L, Stauffer D, Peiffer A, Rattner A, Smallwood P, Li Y, Anderson KL, Lewis RA, Nathans J, Leppert M, Dean M, Lupski JR.
Nat Genet. 1997 Mar;15(3):236-46. Erratum in: Nat Genet. 1997 Sep;17(1):122. doi: 10.1038/ng0997-122a.
- PMID:
- 9054934
Lewis RA, Shroyer NF, Singh N, Allikmets R, Hutchinson A, Li Y, Lupski JR, Leppert M, Dean M.
Am J Hum Genet. 1999 Feb;64(2):422-34.
- PMID:
- 9973280
- PMCID:
- PMC1377752
Details of each submission
From OMIM, SCV000028548.4
# | Ethnicity | Individuals | Chromosomes Tested | Family History | Method | Citations |
---|---|---|---|---|---|---|
1 | not provided | not provided | not provided | not provided | literature only | PubMed (4) |
Description
In 6 of 167 patients with age-related macular dystrophy (ARMD2; 153800), Allikmets et al. (1997) found a gly1961-to-glu (G1961E) alteration in the ABCR gene. The associated pathology ranged from a few tiny juxtafoveal drusen in 1 eye of a patient (age 74 years), to confluent drusen and drusenoid retinal pigment epithelium (RPE) detachments (age 78 years), to various forms of soft to calcified macular drusen and extensive geographic atrophy (more than 1 disc diameter) (ages 81 and 82 years, respectively).
In a study of 150 families with recessive Stargardt disease (STGD1; 248200), Lewis et al. (1999) found that the G1961E mutation was present in 16 of 173 chromosomes in which mutation was identified. G1961E in heterozygous state had previously been associated with age-related macular degeneration. In 150 families with STGD1, a high frequency of ARMD in first- and second-degree relatives was found, suggesting that heterozygosity enhances susceptibility to ARMD.
In a 14-year-old female with cone dystrophy (CORD3; 604116), Kitiratschky et al. (2008) identified compound heterozygosity for a 5882G-A transition in exon 42 of the ABCA4 gene, resulting in the G1961E substitution, and a splice site mutation (601691.0030). The patient, who had onset of disease at 6 years of age, had a red-green defect of color vision, normal glare sensitivity and night vision, RPE atrophy of the macula and peripheral retina, central scotoma, and a reduced cone but normal rod electroretinogram (ERG). Both mutations were also identified in her affected brother, and their unaffected parents were each heterozygous for 1 of the mutations, respectively.
Lek et al. (2016) questioned the pathogenicity of this variant because the ExAC database lists 4 homozygotes with the variant as well as a high allele frequency (0.015) of the variant in the South Asian population.
# | Sample | Method | Observation | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences | |
1 | germline | not provided | not provided | not provided | not provided | not provided | not provided | not provided | not provided |
From Lupski Lab, Baylor-Hopkins CMG, Baylor College of Medicine, SCV000267674.1
# | Ethnicity | Individuals | Chromosomes Tested | Family History | Method | Citations |
---|---|---|---|---|---|---|
1 | not provided | 2 | not provided | yes | research | PubMed (1) |
2 | not provided | 1 | not provided | yes | research | PubMed (1) |
Description
identified in compound heterozygous state in affected individual/s with macular isease
# | Sample | Method | Observation | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences | |
1 | germline | yes | not provided | not provided | not provided | 2 | not provided | not provided | not provided | |
2 | germline | no | not provided | not provided | not provided | 1 | not provided | not provided | not provided |
From Institute of Human Genetics, Univ. Regensburg, Univ. Regensburg, SCV000281939.2
# | Ethnicity | Individuals | Chromosomes Tested | Family History | Method | Citations |
---|---|---|---|---|---|---|
1 | not provided | 48 | not provided | not provided | clinical testing | PubMed (15) |
# | Sample | Method | Observation | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences | |
1 | germline | yes | 335 | not provided | not provided | 48 | not provided | not provided | not provided |
From Knight Diagnostic Laboratories, Oregon Health and Sciences University - CSER-NextGen, SCV000494247.2
# | Ethnicity | Individuals | Chromosomes Tested | Family History | Method | Citations |
---|---|---|---|---|---|---|
1 | not provided | not provided | not provided | not provided | clinical testing | PubMed (1) |
Description
The c.5882G>A (p.Gly1961Glu) missense variant in the ABCA4 gene has been previously reported in multiple individuals affected with Stargardt Disease (Kousal et al., 2014; Fritsche et al., 2012; Burke et al., 2012; Cella et al., 2009). This variant was observed at a significantly higher frequency in affected individuals than in a control population (OR=41.03 (5.4-310.1)). Furthermore, this variant is predicted to lie within a nucleotide binding domain, and in vitro functional assays demonstrated that this variant resulted in decreased ATP-binding capacity and ATP hydrolysis, despite an increase of the total amount of ABCA4 protein (Sun et al., 2000). Multiple in silico algorithms predict this variant to have a deleterious effect (GERP=5.35; CADD = 23.6; PolyPhen = 1.0; SIFT = 0.0). Emory Genetics Laboratory has classified this variant as Pathogenic. Therefore, this collective evidence supports the classification of the c.5882G>A (p.Gly1961Glu) as a Pathogenic variant for Stargardt Disease. We have confirmed this finding in our laboratory using Sanger sequencing.
# | Sample | Method | Observation | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences | |
1 | germline | no | not provided | not provided | not provided | not provided | not provided | not provided | not provided |
From GenomeConnect, ClinGen, SCV000607275.1
# | Ethnicity | Individuals | Chromosomes Tested | Family History | Method | Citations |
---|---|---|---|---|---|---|
1 | not provided | not provided | not provided | not provided | phenotyping only | not provided |
Description
GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant.
# | Sample | Method | Observation | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences | |
1 | unknown | unknown | not provided | not provided | validation | not provided | not provided | not provided | not provided |
From Department Of Genetics, Sultan Qaboos University Hospital, Sultan Qaboos University, SCV000891470.1
# | Ethnicity | Individuals | Chromosomes Tested | Family History | Method | Citations |
---|---|---|---|---|---|---|
1 | not provided | not provided | not provided | not provided | curation | PubMed (1) |
# | Sample | Method | Observation | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences | |
1 | unknown | yes | not provided | not provided | not provided | not provided | not provided | not provided | not provided |
From Mendelics, SCV001135328.1
# | Ethnicity | Individuals | Chromosomes Tested | Family History | Method | Citations |
---|---|---|---|---|---|---|
1 | not provided | not provided | not provided | not provided | clinical testing | not provided |
# | Sample | Method | Observation | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences | |
1 | unknown | unknown | not provided | not provided | not provided | not provided | not provided | not provided | not provided |
From Baylor Genetics, SCV001521357.1
# | Ethnicity | Individuals | Chromosomes Tested | Family History | Method | Citations |
---|---|---|---|---|---|---|
1 | not provided | not provided | not provided | not provided | clinical testing | PubMed (1) |
Description
This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868].
# | Sample | Method | Observation | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences | |
1 | unknown | yes | not provided | not provided | not provided | not provided | not provided | not provided | not provided |
From Institute of Medical Molecular Genetics, University of Zurich, SCV001548126.1
# | Ethnicity | Individuals | Chromosomes Tested | Family History | Method | Citations |
---|---|---|---|---|---|---|
1 | not provided | not provided | not provided | not provided | clinical testing | PubMed (2) |
# | Sample | Method | Observation | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences | |
1 | germline | yes | not provided | not provided | not provided | not provided | not provided | not provided | not provided |
From Laboratory of Medical Genetics, National & Kapodistrian University of Athens, SCV001976708.1
# | Ethnicity | Individuals | Chromosomes Tested | Family History | Method | Citations |
---|---|---|---|---|---|---|
1 | not provided | not provided | not provided | not provided | clinical testing | PubMed (2) |
Description
PM1, PM3, PM5, PP2, PP3, PP5
# | Sample | Method | Observation | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences | |
1 | maternal | yes | not provided | not provided | not provided | not provided | not provided | not provided | not provided |
From 3billion, SCV002058783.1
# | Ethnicity | Individuals | Chromosomes Tested | Family History | Method | Citations |
---|---|---|---|---|---|---|
1 | not provided | 1 | not provided | not provided | clinical testing | PubMed (1) |
Description
Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000007888, PMID:9295268, PS1_S). A different missense change at the same codon has been reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000236140, PMID:22427542,NULL, PM5_M). In silico tool predictions suggest damaging effect of the variant on gene or gene product (REVEL: 0.76, 3CNET: 0.857, PP3_P). A missense variant is a common mechanism associated with Stargardt disease 1 (PP2_P). Therefore, this variant is classified as likely pathogenic according to the recommendation of ACMG/AMP guideline.
# | Sample | Method | Observation | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences | |
1 | germline | yes | 1 | not provided | not provided | 1 | not provided | not provided | not provided |
From Genome-Nilou Lab, SCV002100408.1
# | Ethnicity | Individuals | Chromosomes Tested | Family History | Method | Citations |
---|---|---|---|---|---|---|
1 | not provided | not provided | not provided | not provided | clinical testing | PubMed (1) |
# | Sample | Method | Observation | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences | |
1 | germline | yes | not provided | not provided | not provided | not provided | not provided | not provided | not provided |
From Institute of Human Genetics, University of Leipzig Medical Center, SCV002526676.3
# | Ethnicity | Individuals | Chromosomes Tested | Family History | Method | Citations |
---|---|---|---|---|---|---|
1 | not provided | not provided | not provided | not provided | clinical testing | PubMed (1) |
Description
Criteria applied: PM3_VSTR,PM5_STR,PP1_STR,PS3_MOD,PP3
# | Sample | Method | Observation | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences | |
1 | unknown | yes | not provided | not provided | not provided | not provided | not provided | not provided | not provided |
From Arcensus, SCV002564625.1
# | Ethnicity | Individuals | Chromosomes Tested | Family History | Method | Citations |
---|---|---|---|---|---|---|
1 | not provided | not provided | not provided | not provided | clinical testing | PubMed (1) |
# | Sample | Method | Observation | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences | |
1 | germline | yes | not provided | not provided | not provided | not provided | not provided | not provided | not provided |
From MGZ Medical Genetics Center, SCV002581171.1
# | Ethnicity | Individuals | Chromosomes Tested | Family History | Method | Citations |
---|---|---|---|---|---|---|
1 | not provided | 5 | not provided | not provided | clinical testing | PubMed (1) |
# | Sample | Method | Observation | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences | |
1 | germline | yes | not provided | not provided | not provided | 5 | not provided | not provided | not provided |
From Victorian Clinical Genetics Services, Murdoch Childrens Research Institute, SCV002767263.1
# | Ethnicity | Individuals | Chromosomes Tested | Family History | Method | Citations |
---|---|---|---|---|---|---|
1 | not provided | not provided | not provided | not provided | clinical testing | PubMed (8) |
Description
Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with Stargardt disease (MIM#248200) and other eye conditions (OMIM). (I) 0106 - This gene is associated with autosomal recessive disease (OMIM). (I) 0115 - Variants in this gene are known to have variable expressivity (PMID: 31522899). (I) 0200 - Variant is predicted to result in a missense amino acid change from glycine to glutamic acid. (I) 0252 - This variant is homozygous. (I) 0305 - Variant is present in gnomAD >=0.01 and <0.03 for a recessive condition (v2: 1271 heterozygotes, 10 homozygotes). (I) 0309 - An alternative amino acid change at the same position has been observed in gnomAD (v2) (26 heterozygotes, 0 homozygotes). (I) 0502 - Missense variant with conflicting in silico predictions and high conservation. (I) 0600 - Variant is located in the annotated NBD2 domain (PMID: 29847635). (I) 0701 - Other missense variants comparable to the one identified in this case have very strong previous evidence for pathogenicity. p.(Gly1961Ala) has been previously reported in patients with Stargardt disease (ClinVar, PMID: 22427542). (SP) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals with mild and later onset Stargardt disease (ClinVar, PMID: 22661473, PMID: 28327576, PMID: 28130426, PMID: 29925512). (SP) 1002 - This variant has moderate functional evidence supporting abnormal protein function, where transfected cells displayed reduced ATPase activity and substrate binding (PMID: 29847635). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign
# | Sample | Method | Observation | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences | |
1 | germline | yes | not provided | not provided | not provided | not provided | not provided | not provided | not provided |
From Neuberg Centre For Genomic Medicine, NCGM, SCV004048390.1
# | Ethnicity | Individuals | Chromosomes Tested | Family History | Method | Citations |
---|---|---|---|---|---|---|
1 | not provided | not provided | not provided | not provided | clinical testing | PubMed (1) |
Description
This variant c.5882G>A (p.Gly1961Glu) in ABCA4 gene has been observed in many individuals with autosomal recessive Stargardt disease, and has been found in trans (on the opposite chromosome) from many different pathogenic variants (PMID: Stone et al., 2017; Riera et al., 2017). This variant is present in population databases (rs1800553, ExAC 1.5%), including several homozygous individuals, and has an allele count higher than expected for a pathogenic variant (Kobayashi et al., 2017). However, this variant appears to be significantly enriched in individuals with Stargardt compared to the general population (Lee et al., 2017). This variant appears to be associated with milder and/or later onset disease (Lee et al., 2017). This variant has been reported to affect ABCA4 protein function (Sun et al. 2000). The amino acid Gly at position 1961 is changed to a Glu changing protein sequence and it might alter its composition and physico-chemical properties. The variant is predicted to be damaging by SIFT and the residue is conserved across species. The amino acid change p.Gly1961Glu in ABCA4 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Pathogenic.
# | Sample | Method | Observation | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences | |
1 | germline | yes | not provided | not provided | not provided | not provided | not provided | not provided | not provided |
From Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center, SCV004806246.1
# | Ethnicity | Individuals | Chromosomes Tested | Family History | Method | Citations |
---|---|---|---|---|---|---|
1 | not provided | not provided | not provided | not provided | clinical testing | PubMed (1) |
# | Sample | Method | Observation | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Origin | Affected | Number tested | Tissue | Purpose | Method | Individuals | Allele frequency | Families | Co-occurrences | |
1 | germline | unknown | not provided | not provided | not provided | not provided | not provided | not provided | not provided |
Last Updated: Nov 24, 2024